Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04744974 · ClinicalTrials.gov registry record · Phase 2
Remotely Administered Diet Intervention to Impact Symptom Burden in Myeloproliferative Neoplasm
A Phase 2 study, sponsored by University of California, Irvine.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT04744974 is a Phase 2 study that has completed, run by University of California, Irvine. The registered enrollment target is 28 participants.
The verdict
NCT04744974, a Phase 2 study, has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
Myeloproliferative Neoplasm (MPN) is a chronic blood cancer without cure. The major clinical issues in MPN are 1) an increased risk of blood clots 2) symptoms thought to be driven by chronic inflammation which in some cases can be debilitating and 3) progression to acute leukemia. The current management of MPN focuses on preventing blood clots and relieving symptoms. However, treatments that reduce symptoms such as JAK inhibitors are limited to late stage MPN patients and have significant side effects including immunosuppression, reduction in platelets, and increased risk of skin cancer. Therefore, low risk interventions are sorely needed for MPN patients that can reduce symptoms. Diet represents a low risk way to reduce inflammation, specifically a Mediterranean diet has been found to reduce inflammation in cardiovascular disease. There has been a recently completed clinical trial that demonstrated MPN patients can adopt a Mediterranean diet if given dietician counseling and curriculum. However, in order to reach a larger group of people a fully remotely administered study is necessary. This is a feasibility study to determine.
Interventions
- BEHAVIORAL Diet intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2021-01-21 |
| Est. Completion | 2021-12-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04744974
The ClinicalTrials.gov registry entry for NCT04744974 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Diet intervention is the first listed.
NCT04744974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04744974 about?
NCT04744974 is a clinical study titled "Remotely Administered Diet Intervention to Impact Symptom Burden in Myeloproliferative Neoplasm". Myeloproliferative Neoplasm (MPN) is a chronic blood cancer without cure. The major clinical issues in MPN are 1) an increased risk of blood clots 2) symptoms thought to be driven by chronic inflammation which in some cases can be debilitating and 3) progression to acute leukemia. The current manage...
What is the current status of trial NCT04744974?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2021-01-21. Estimated completion is 2021-12-06.
What interventions are being tested in trial NCT04744974?
The interventions under investigation include: Diet intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT04744974?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.